Use these selected concepts to distinguish registration requirements from clinical recommendations and apply individual rules to practical dental scenarios. Start with registration and documentation, then review screening, coordinated care, dental pain and overdose reversal. The examples illustrate decisions without establishing prescribing authority or replacing patient assessment.
Registration and practice boundaries
1. Prescribing and administering count as dispensing
Under federal rules, dispensing includes both prescribing and administering, so a dentist handling any Schedule II–V controlled substance generally needs DEA registration or an applicable exemption, which must be evaluated separately; dentistry alone does not trigger registration.
Worked example: A dentist who intends to prescribe a Schedule II analgesic after oral surgery cannot skip registration on the grounds that a community pharmacy, not the office, will supply the medication.
Mistake to avoid: Assuming only keeping office stock of controlled substances triggers the registration requirement.
2. Federal registration depends on state authority
DEA registration rests on state authorization and never expands a dentist's prescribing authority or permitted schedules beyond what the licensing state grants; a limited SCRA exception for qualifying servicemembers and spouses requires separate assessment of all conditions.
Worked example: A dentist registered in State A remains subject to State A's schedule limits and cannot lawfully prescribe controlled substances from a new office located in State B without that state's own authorization.
Mistake to avoid: Treating a federal DEA registration number as nationwide authority to prescribe anywhere.
3. Principal practice locations determine registration needs
A separate registration is required for each principal place of business or professional practice at one general physical location where controlled substances are manufactured, distributed, imported, exported, or dispensed; location exceptions under § 1301.12(b) require separate examination.
Worked example: A dentist with principal professional practice offices in two states, both handling controlled substances and with no applicable exception, must obtain separate DEA registrations and state authorization in each state.
Mistake to avoid: Assuming one DEA registration automatically covers every office the dentist operates.
4. A mailing address cannot replace the registered premises
The registered address must be the physical location of the principal place of business or professional practice where the relevant controlled-substance activities occur; a PO Box may be added in limited circumstances, and DEA correspondence may use a different mailing address.
Worked example: A dentist registers using the street address of the office where controlled substances are dispensed and lists a PO Box separately as the mailing address for DEA correspondence.
Mistake to avoid: Supplying only a PO Box as the registered practice address on the DEA application.
Reference: [1]
5. A registered home remains a controlled premises
When a practitioner registers a home as the principal place of professional practice, it becomes a controlled premises subject to unannounced inspections and administrative warrants, with established recordkeeping and security requirements and applicable state, local, or tribal laws.
Worked example: A dentist registering a home as the practice address remains subject to unannounced inspections, administrative warrants, and established recordkeeping and security requirements, while applicable state, local, and tribal laws still govern the home practice.
Mistake to avoid: Assuming a home address places the registered premises outside DEA inspection rules.
Reference: [1]
6. Scheduling differences require the more restrictive rule
Federal scheduling does not settle every state requirement: certain substances may be scheduled differently under state law, and when requirements differ, registrants must comply with the more restrictive one, though scheduling alone does not confer prescribing authority.
Worked example: If a hypothetical state scheduled a substance more restrictively than federal law, the dentist would follow the stricter state requirement rather than the federal schedule alone, since scheduling does not itself establish prescribing authority.
Mistake to avoid: Treating a federal schedule list as a complete reference for state prescribing requirements.
Reference: [5]
7. The DATA-Waiver repeal removed a separate federal barrier
The repeal removed the federal DATA-Waiver requirement and the associated X-waiver number for prescribing buprenorphine for opioid use disorder; DEA stated registrants need take no action, though state authority and remaining federal requirements still govern.
Worked example: An otherwise authorized practitioner needs no replacement certificate solely because the X-waiver requirement ended; state authority, professional scope, and remaining federal requirements still govern, and the MATE Act education change is separate.
Mistake to avoid: Reading the repeal as granting dentists unrestricted authority to prescribe buprenorphine for OUD.
Reference: [1]
MATE Act education and attestation
8. The obligation begins at the first applicable registration
The training requirement applies from the first registration or renewal on or after June 27, 2023, and no qualified practitioner is required to complete it more than once; the affirmation does not recur at future renewals, and the solely-veterinarian exception does not exempt dentists.
Worked example: A dentist who attested to the training at the first applicable registration on or after June 27, 2023 does not repeat this federal affirmation solely for the next renewal, though state education requirements remain applicable.
Mistake to avoid: Confusing the one-time federal attestation with recurring state continuing education requirements.
9. Graduation alone does not establish qualifying education
The graduation pathway requires accredited United States schooling in good standing within the applicable five-year condition, plus a curriculum containing the required qualifying training; DEA's FAQ states the window both as a rolling past-five-years rule and an older summary anchored to June 27, 2023, so individual date eligibility must be checked against current requirements.
Worked example: A dentist who graduated in good standing from an accredited United States dental school within the applicable five-year window still needs documentation showing the curriculum included the required eight hours of qualifying training.
Mistake to avoid: Assuming any recent dental degree automatically proves the education pathway without checking accreditation, standing, timing, or curriculum content.
Reference: [4]
10. Eligible training hours can accumulate
The eight hours need not occur in one session and may be satisfied through cumulative continuing education hours, provided each counted session carries qualifying content and comes from an eligible provider or carries an eligible approval; a convenient format alone does not establish that a course qualifies.
Worked example: A dentist completes three qualifying hours with the American Dental Association, two with an ACCME-accredited provider, and three more with the American Dental Association, reaching eight eligible hours across separate sessions.
Mistake to avoid: Adding session lengths to eight hours without confirming each session's content and provider satisfy the applicable requirements.
11. Provider eligibility is separate from course relevance
Relevant subject matter alone does not make a course count; the provider or approval relationship must also qualify. The American Dental Association and the American Association of Oral and Maxillofacial Surgeons are examples, not an exhaustive list, and provider eligibility does not remove the content or hour requirements, so the full current provider and approval categories should be used when evaluating a particular course.
Worked example: An eight-hour opioid course provided directly by the American Dental Association qualifies by provider, while an identical course from an unidentified independent group still requires checking its approval relationship.
Mistake to avoid: Counting any course that mentions opioids as qualifying without verifying the provider's or approver's eligibility under current categories.
Reference: [3]
12. Qualifying earlier training can count
Previous training on treating and managing patients with opioid or other substance use disorders can count toward the requirement, including past DATA-Waiver training, when it satisfies the applicable content and provider conditions; repeal of the DATA-Waiver does not erase the educational credit described by DEA.
Worked example: A dentist who completed eight qualifying hours from an eligible provider before the MATE requirement's enactment may count that documented training toward the eight-hour attestation requirement.
Mistake to avoid: Dismissing pre-enactment substance use training as ineligible when it satisfied the applicable content and provider conditions.
Reference: [4]
13. Retaining certificates differs from submitting them
DEA recommends that practitioners keep training certificates or other documentation of completion, but these documents do not need to be submitted to DEA for review when applying initially or renewing registration.
Worked example: A dentist finishing an eligible eight-hour course files the certificate in her own records and later attests on the registration form that she completed the required training, without uploading anything to DEA.
Mistake to avoid: Assuming that because no upload is required, attesting without actually completing qualifying training is acceptable.
Reference: [4]
Records for different controlled-substance activities
14. Prescribing has a qualified federal record exemption
Under Part 1304, a registered individual practitioner generally need not keep records of Schedule II–V substances prescribed in the lawful course of professional practice, subject to § 1304.06, unless the prescription serves maintenance or detoxification treatment, which requires records.
Worked example: A dentist lawfully prescribing a short course of a Schedule III analgesic to a pharmacy for a patient's dental pain relies on the exemption, unlike a prescription serving as maintenance or detoxification treatment, which requires records.
Mistake to avoid: Telling colleagues that controlled-substance prescriptions never generate any federal recordkeeping obligation under any circumstance.
Reference: [7]
15. Other dispensing requires controlled-substance records
A registered individual practitioner must keep records, as described in § 1304.04, for Schedule II–V controlled substances dispensed other than by prescribing or administering in the lawful course of professional practice.
Worked example: A dentist with lawful dispensing authority who provides office-stock tablets for a patient to take home keeps the required § 1304.04 records, unlike a prescription transmitted to a pharmacy, which falls under the prescribing provision.
Mistake to avoid: Extending the prescribing exemption to every dispensing activity simply because the practitioner holds a registration.
Reference: [7]
16. Regular charged administration changes the exemption
The administration record exemption does not apply when a practitioner regularly dispenses or administers controlled substances and charges patients, separately or bundled with other service charges; records for maintenance or detoxification administration are required independently of those two conditions.
Worked example: A practice that routinely administers a Schedule IV sedative and includes its cost in one combined procedure fee keeps administration records, because bundling the charge into the service price does not restore the exemption.
Mistake to avoid: Reviewing only itemized drug charges on invoices and concluding bundled administration costs never trigger recordkeeping duties.
Reference: [7]
Issuing controlled-substance prescriptions
17. A valid prescription needs a legitimate professional purpose
A controlled-substance prescription is effective only when issued for a legitimate medical purpose by a practitioner acting in the usual course of professional practice. The prescribing practitioner bears responsibility, while the dispensing pharmacist carries a corresponding, separate responsibility. Formal completeness alone does not establish substantive validity.
Worked example: A dentist hands a colleague a fully completed prescription form whose stated purpose is supplying the colleague's own general dispensing to patients; because that purpose falls outside legitimate professional treatment, the order is not a valid prescription even though every field is filled in.
Mistake to avoid: Treating a formally complete prescription as proof of substantive validity despite its illegitimate stipulated purpose.
Reference: [8]
18. Communicating a prescription is distinct from issuing it
A prescription that an individual practitioner has lawfully issued may be communicated to a pharmacist by the practitioner's employee or agent. This communication permission does not make the employee the prescriber, because only an individual practitioner may issue a controlled-substance prescription.
Worked example: After a dentist issues a prescription, the front-desk employee relays it to the pharmacy using a method permitted for that communication; the employee is transmitting the dentist's issued order, not acting as the prescriber or choosing the treatment.
Mistake to avoid: Reading an employee's permission to relay prescriptions as independent authority to select and issue treatment.
Reference: [8]
19. Prescription completeness includes patient, drug and practitioner details
Controlled-substance prescriptions must be dated as of, and signed on, the day of issue, and must bear the patient's full name and address, the drug name, strength, dosage form, quantity prescribed, directions for use, and the practitioner's name, address and registration number.
Worked example: A paper prescription correctly names the patient and the drug but leaves out the quantity prescribed; because a required element is missing, the prescription is incomplete even though the practitioner's registration number appears and the document is signed on the issue day.
Mistake to avoid: Checking only the registration number while overlooking patient details, drug particulars or directions for use.
Reference: [8]
20. Computer-printed paper prescriptions still need manual signatures
Where an oral order is not permitted, paper prescriptions may be written in ink or indelible pencil, typed, or printed on a computer printer, but they must be manually signed by the practitioner. Printing the practitioner's name does not satisfy the manual-signature requirement, and electronic prescribing follows separate requirements.
Worked example: A dentist's office prints a complete paper prescription for a drug for which no oral order is permitted, with the dentist's name typed at the signature line; because the practitioner never manually signs it, the printed document does not meet the paper-prescription requirement.
Mistake to avoid: Confusing a computer-printed paper document lacking a manual signature with a compliant electronic prescription.
Reference: [8]
21. Patient prescriptions cannot supply general office stock
Under 21 CFR Part 1306, a prescription must serve a legitimate medical purpose for an identified patient; it cannot function as an ordering mechanism to replenish a practitioner's general dispensing stock for unspecified future patients.
Worked example: A dentist writes a prescription labeled for office supply to restock the practice's shared controlled-substance shelf; it is invalid for that purpose because it is not issued for a specific patient's treatment.
Mistake to avoid: Using a routine patient prescription to replenish the office's shared dispensing stock for future patients.
Reference: [8]
Controlled-substance disposal boundaries
22. Practitioner inventory and patient leftovers have different frameworks
Part 1317 separates disposal rules into subpart A for controlled substances lawfully possessed by registered practitioners and subpart B for those held by non-registrants, so the same medication follows different frameworks depending on who holds it.
Worked example: Expired midazolam vials in a dental practice's registrant inventory fall under subpart A, whereas a patient's leftover home prescription tablets fall under the non-registrant subpart B framework.
Mistake to avoid: Assuming identical medication creates identical disposal permissions regardless of whether a registrant or patient holds it.
Reference: [9]
23. Lawful inventory disposal requires an authorized route
A registered practitioner disposing of lawfully possessed controlled-substance inventory must use one of four authorized routes: Subpart C-compliant on-site destruction, delivery to a registered reverse distributor, eligible return or recall, or requesting DEA Special Agent in Charge assistance.
Worked example: A dental practice with expired controlled-substance stock promptly delivers it to a reverse distributor's registered location by common or contract carrier pick-up, one of the authorized registrant disposal routes under Part 1317.
Mistake to avoid: Placing expired controlled-substance office inventory into ordinary waste disposal instead of an authorized Part 1317 route.
Reference: [9]
Alcohol screening and assessment
24. Choose a validated adult alcohol screener
For adult screening for unhealthy alcohol use, the USPSTF recommends two brief validated tools—the three-question AUDIT-C and the Single Alcohol Screening Question—while advising against CAGE, which only captures patients already experiencing consequences and misses prevention opportunities.
Worked example: An adult dental screening workflow uses the AUDIT-C's three frequency-and-quantity questions with its actual scoring, rather than CAGE, which the USPSTF does not recommend because it misses patients who could benefit from brief intervention.
Mistake to avoid: Screening adults with CAGE alone, assuming it identifies the full spectrum of unhealthy alcohol use.
Reference: [16]
25. A positive alcohol screen calls for assessment
A positive heavy-drinking screen signals the need for further assessment of the patient's drinking pattern and AUD symptoms. Screening alone does not establish an alcohol use disorder diagnosis, which requires applying the relevant diagnostic criteria through a complete assessment.
Worked example: A patient reports one heavy-drinking occasion during routine screening; the clinician next asks about the drinking pattern and AUD symptoms rather than recording an AUD diagnosis.
Mistake to avoid: Recording a diagnosis of AUD immediately after a positive heavy-drinking screen result.
Reference: [16]
26. The single alcohol question counts qualifying days
NIAAA's adult single-question screen asks how many times in the past year the patient had 4 or more drinks (women) or 5 or more (men) in a day; any response of one or more warrants follow-up assessment.
Worked example: A male patient reports two days in the past year on which he had five drinks; this single positive response warrants follow-up assessment of his drinking, not a diagnosis.
Mistake to avoid: Requiring repeated weekly heavy-drinking episodes before acting on a single qualifying day.
Reference: [16]
27. Weekly alcohol volume can reveal a different pattern
Estimate typical weekly consumption by multiplying drinking days by drinks per typical drinking day. Weekly heavy-drinking thresholds can flag a pattern even when no single day reaches the daily heavy-drinking definition for that patient's sex.
Worked example: A man drinks four drinks on each of four days weekly, totaling 16 drinks; this exceeds the 15-drink weekly threshold even though no single day reached five drinks.
Mistake to avoid: Evaluating only the largest single drinking day and ignoring the calculated weekly total.
Reference: [16]
28. Alcohol biomarkers supplement the drinking history
Laboratory tests support assessment but never replace drinking self-report. NIAAA distinguishes indirect markers such as GGT and CDT, which reflect consumption indirectly, from newer assays directly measuring alcohol metabolites such as PEth and EtG.
Worked example: A laboratory result is already available for a new patient; the clinician still takes a full drinking history because no biomarker substitutes for self-report measures.
Mistake to avoid: Skipping the drinking history because an unspecified laboratory result came back normal.
Reference: [16]
29. AUD severity depends on assessed diagnostic symptoms
NIAAA distinguishes mild AUD with two or three assessed symptoms, moderate AUD with four or five, and severe AUD with six or more, based on an 11-item Alcohol Symptom Checklist built on the diagnostic criteria for AUD.
Worked example: A patient's completed symptom assessment confirms four distinct AUD diagnostic symptoms, so under the NIAAA framework her AUD is categorized as moderate rather than mild or severe.
Mistake to avoid: Counting the number of drinks consumed, positive screening responses, or repeated descriptions of one symptom as separate diagnostic symptoms.
Reference: [16]
30. Abrupt alcohol cessation can require medical safety planning
For patients with AUD, abruptly stopping alcohol can cause alcohol withdrawal, which can be life threatening, so NIAAA advises being cautious and considering the need for medically managed withdrawal.
Worked example: A patient with assessed AUD announces he will quit drinking immediately; his clinician recognizes the withdrawal risk and arranges an appropriate medical safety assessment instead of offering unqualified reassurance.
Mistake to avoid: Giving a patient a home withdrawal schedule or presenting abrupt alcohol cessation as universally safe for everyone with AUD.
Reference: [16]
Opioid treatment foundations
31. Partial agonism does not mean an absence of opioid effects
As an opioid partial agonist, buprenorphine can still produce opioid effects, including euphoria and respiratory depression at low to moderate doses; SAMHSA describes these effects as weaker than those of full opioid agonists, not absent.
Worked example: A team member calls buprenorphine incapable of causing respiratory depression because it is a partial agonist; the classification actually means its opioid effects, including respiratory depression, are weaker than full agonists' effects.
Mistake to avoid: Converting the partial agonist distinction into a zero-risk claim that buprenorphine cannot produce opioid effects in any patient.
Reference: [12]
32. OUD medication and overdose reversal serve different purposes
Buprenorphine's OUD treatment role includes diminishing the effects of physical dependency to opioids, such as withdrawal symptoms and cravings, whereas naloxone is designed to rapidly reverse opioid overdose and is a temporary treatment whose effects do not last long.
Worked example: After a patient's opioid overdose is reversed with naloxone, the team identifies it as emergency reversal only, not as continuing treatment for his withdrawal symptoms and cravings, which buprenorphine addresses in OUD care.
Mistake to avoid: Treating ongoing opioid use disorder treatment and emergency overdose reversal as interchangeable roles for the same medication purpose.
Tobacco assessment and behavioral support
33. Tobacco status and readiness answer different questions
The 2008 Public Health Service framework sorts patients by two separate questions: whether tobacco use is current and whether the patient is willing to quit now. Status categories include current users ready to quit, current users not ready, former users, and people who never regularly used tobacco.
Worked example: A hygienist documents a patient as a current smoker who is not willing to make a quit attempt today, while another record shows a former smoker whose relapse-prevention needs are considered separately.
Mistake to avoid: Charting a patient's unwillingness to quit as evidence that tobacco use has stopped.
Reference: [18]
34. Practical tobacco counseling connects triggers with coping
The 2008 Public Health Service guideline describes practical counseling as problem-solving and skills training: clinicians help patients identify events, internal states, or activities that raise smoking or relapse risk, then identify and practice coping or problem-solving skills matched to those danger situations.
Worked example: A patient names afternoon coffee breaks with smoking coworkers as a trigger, then rehearses with the clinician a revised break routine, such as walking a different route, without any promise of cessation.
Mistake to avoid: Offering only general encouragement while ignoring the specific trigger the patient identified.
Reference: [18]
Patient participation and coordinated care
35. Shared decisions require informed patient participation
SAMHSA recommends patient-centered decision making, and CDC describes pain care decisions made together by patients and clinicians, including discussing realistic benefits, known risks, and patient and clinician values and preferences before selecting among appropriate options.
Worked example: Before choosing among appropriate pain options, the clinician reviews realistic benefits and known risks with the adult outpatient, asks about the patient's values and preferences, and the decision is reached together.
Mistake to avoid: Deciding the plan alone, then describing it to the patient and calling it shared decision making.
36. Whole-person treatment includes coordinated services
SAMHSA states buprenorphine should be prescribed as part of a comprehensive treatment plan including counseling and other services for a whole-person approach, and recommends collaborating with other disciplines to facilitate access to medications and referrals such as case management.
Worked example: A dental clinician documents contact with the patient's authorized opioid use disorder care team so medication and referral services stay coordinated within the broader comprehensive plan rather than standing alone.
Mistake to avoid: Prescribing or noting the medication and then skipping any coordination with the patient's other treating clinicians.
37. Access barriers belong in the care plan
CDC calls for equitable pain care to include attention to mitigating potential barriers, such as linguistically tailored care and cost-assistance programs, while SAMHSA's treatment-planning curriculum addresses stigma, trauma, and social determinants of health affecting substance use and recovery.
Worked example: A dentist learns the patient prefers Spanish-language instructions and worries about costs, so the plan includes translated materials and a discussion of cost-assistance options for the recommended therapy.
Mistake to avoid: Reading a patient's difficulty reaching the clinic as proof she rejects treatment rather than faces an access barrier.
38. Ask permission when opening an alcohol discussion
When transitioning from screening to a brief intervention, NIAAA recommends requesting the patient's permission to discuss alcohol and reassuring them that such discussion is a normal part of the exam, like any other health behavior.
Worked example: After a dental patient's screen suggests heavy drinking, the dentist says alcohol use came up in the exam and asks whether the patient is willing to discuss it today.
Mistake to avoid: Delivering an unrequested lecture about drinking risks immediately after screening, before the patient has agreed to the conversation.
Reference: [17]
39. Respect autonomy without withdrawing clear advice
NIAAA advises clinicians to avoid arguing with patients who resist change while still recognizing their autonomy, offering clear individualized recommendations and support, and keeping direct, nonjudgmental, constructive communication open across visits.
Worked example: A patient declines to cut back after feedback; the dentist acknowledges the decision is the patient's, restates the health concern once, and leaves the discussion open for future visits.
Mistake to avoid: Treating respect for autonomy as permission either to argue persistently or to stay silent about drinking concerns.
Reference: [17]
40. A change plan specifies actions and follow-up
NIAAA recommends collaborating on a change plan that specifies the goal, timing, reasons, strategies, supportive people, and ways to handle roadblocks, then revisiting the agreed steps at subsequent appointments to sustain motivation.
Worked example: A patient agrees to record daily drink counts and identify a friend who supports cutting back; the dentist notes both steps and plans to review the record at the next visit.
Mistake to avoid: Accepting a vague intention to drink less sometime as a complete change plan with goals, strategies, and follow-up.
Reference: [17]
41. Moderate or severe AUD usually needs more than brief advice
NIAAA notes that for people with moderate to severe AUD, a brief intervention alone is probably not sufficient; such patients can benefit from evidence-based behavioral healthcare, FDA-approved medications, mutual support groups, or combinations, with referrals following applicable consent and confidentiality requirements.
Worked example: A dentist's assessment finds severe AUD; the dentist discusses treatment options and, with the patient's consent, supports referral to specialty care rather than treating brief advice as the complete plan.
Mistake to avoid: Treating a patient's referral hesitation as a reason to stop discussing access barriers.
Reference: [17]
Dental pain and opioid prescribing principles
42. CDC’s opioid pain guideline has defined boundaries
The CDC 2022 guideline, per Box 2, covers outpatient pain care for adults 18 or older, excludes sickle cell disease, cancer, and palliative or end-of-life pain, and is not focused on opioids prescribed for opioid use disorder; exclusion never means withholding appropriate pain care.
Worked example: A 16-year-old with toothache falls outside CDC's population but within the ADA guidance's age range of 12 or older when dental care is not immediately available.
Mistake to avoid: Applying one national guideline uniformly to every patient age and indication.
43. Pain duration determines the guideline category
CDC's 2022 guideline defines acute pain as lasting less than one month, subacute pain as one to three months, and chronic pain as more than three months; these duration categories do not by themselves diagnose a cause or determine treatment.
Worked example: A patient's pain lasting two weeks is acute, pain present for two months is subacute, and pain persisting five months is chronic under CDC's definitions, without those labels alone indicating the cause.
Mistake to avoid: Classifying a patient's pain category by its intensity instead of its duration.
Reference: [11]
44. Nonopioid options can effectively manage specified dental pain
The ADA states NSAIDs like ibuprofen or naproxen, alone or with acetaminophen, can effectively manage pain in patients aged 12 or older after extraction or with toothache when dental care is not immediately available; no dosing regimen is set, and temporary relief does not replace definitive dental treatment.
Worked example: For an eligible 15-year-old with toothache and no immediately available dental care, nonopioid options belong in the assessment while definitive dental treatment or referral is arranged.
Mistake to avoid: Extending the ADA's effectiveness statement to every age or clinical circumstance.
45. Acute opioid decisions require an anticipated net benefit
Within CDC's adult outpatient scope, clinicians should maximize appropriate nonpharmacologic and nonopioid therapies and consider opioids for acute pain only when anticipated benefits to the patient outweigh risks, after discussing realistic benefits and known risks.
Worked example: A dentist evaluating acute post-extraction pain in an adult first assesses suitable nonpharmacologic and nonopioid options, then discusses realistic benefits and known risks before deciding whether opioids could help.
Mistake to avoid: Treating a high pain score alone as an automatic justification for prescribing an opioid.
Reference: [11]
46. Longer-duration opioid planning includes function and an exit plan
For subacute or chronic pain within CDC's scope, nonopioid therapies are preferred; before starting opioids, clinicians should establish pain and function goals with patients and consider how therapy would be discontinued if benefits do not outweigh risks.
Worked example: Before considering an opioid for a patient's months-long orofacial pain, a dentist documents functional goals, such as returning to work, and how therapy would end if benefits fall short.
Mistake to avoid: Continuing an opioid prescription indefinitely without revisiting whether it still benefits the patient's function.
Reference: [11]
47. Initial opioid formulation differs from a continuation decision
When starting opioid therapy for acute, subacute, or chronic pain within CDC's outpatient scope, the guideline recommends immediate-release opioids rather than extended-release or long-acting formulations; this initiation recommendation does not direct changes to established treatment.
Worked example: A dentist initiating a first opioid prescription for severe acute dental pain selects an immediate-release product, while separately reviewing any established regimen through its own clinical decision.
Mistake to avoid: Reading the initiation recommendation as an automatic order to switch every existing ER/LA prescription.
Reference: [11]
48. Clinical recommendations must remain individualized
CDC describes its 2022 guideline as voluntary support for clinical judgment and person-centered decision-making, explicitly stating its recommendations should not be applied as inflexible standards of care across patient populations by clinicians, systems, payers, or governments.
Worked example: Two adults with chronic pain of similar duration receive different plans because one has kidney disease and the other has different work demands and treatment preferences.
Mistake to avoid: Applying a guideline recommendation identically to every patient as an inflexible treatment mandate.
Reference: [11]
49. Temporary toothache relief must lead to definitive care
The 2024 ADA toothache guide restricts its temporary pharmacologic recommendations to settings where definitive dental treatment is unavailable, and instructs patients to call if pain does not lessen or if referral within two to three days is impossible.
Worked example: A clinician managing a toothache without definitive treatment available arranges referral for pulpectomy within two days and instructs the patient to call if pain worsens or does not lessen.
Mistake to avoid: Telling a patient that improving pain means the dental problem is finished and no follow-up visit is needed.
Reference: [15]
50. Medication review includes supplements and nonprescribed substances
Before temporary analgesic care, the 2024 ADA guide directs clinicians to review medical and social history, including illicit and recreational drug use, plus current medications and supplements, to avoid overdose and adverse drug-drug interactions.
Worked example: During history-taking for temporary toothache care, a clinician records the patient's reported herbal supplement and occasional recreational drug use alongside prescribed medicines before any analgesic decision.
Mistake to avoid: Relying only on the pharmacy prescription list and skipping questions about supplements or recreational drug use.
Reference: [15]
51. Available PDMP information informs co-prescribing assessment
When available, the state PDMP should be reviewed to identify co-prescribed controlled substances; if the patient already receives opioids for chronic pain, the guide says to prioritize nonopioid analgesics, a recommendation that does not itself direct changes to established opioid therapy.
Worked example: Reviewing an available PDMP shows an existing opioid prescription for chronic pain, so the clinician weighs nonopioid analgesic options first, while the recommendation itself does not direct changes to that established therapy.
Mistake to avoid: Skipping PDMP review because it is optional, or automatically discontinuing a patient's established chronic opioid prescription.
Reference: [15]
52. Avoid routine just-in-case opioid prescriptions
The 2024 ADA toothache guide advises against routinely issuing delayed, just-in-case opioid prescriptions intended for possible breakthrough pain; instead, patients should be told to call if pain fails to lessen while awaiting definitive dental treatment.
Worked example: After providing a temporary nonopioid plan and call-back instructions for uncontrolled pain, a clinician declines to write an extra opioid prescription for unspecified future breakthrough pain.
Mistake to avoid: Adding a just-in-case opioid prescription to every toothache plan as a standard contingency for possible breakthrough pain.
Reference: [15]
53. The chairside opioid option has explicit medication exclusions
Within the 2024 ADA chairside guide's temporary toothache pathway, the described opioid combination option should not be offered to patients taking gabapentinoids, central nervous system active medications such as benzodiazepines, antidepressants, anticonvulsants or narcotics, or patients already taking opioids for other medical reasons.
Worked example: A 20-year-old patient aged over 12 with pulpitis, seeking temporary care because definitive treatment is unavailable, reports taking a benzodiazepine; under this guide's pathway, the opioid combination option is excluded, without changing her existing medicine.
Mistake to avoid: Offering the guide's opioid option to a benzodiazepine patient while dropping its stated exclusions.
Reference: [15]
54. Opioid consent includes consequences beyond pain relief
When opioids are prescribed under the 2024 ADA guide, clinicians should obtain informed consent, from the parent or guardian for minors, covering physiological dependence, substance misuse risk, respiratory depression, and adverse effects on driving or operating machinery, with particular attention to adolescents and young adults.
Worked example: For a 15-year-old adolescent, the consent discussion includes the parent or guardian and addresses dependence, misuse, respiratory depression and impairment, not merely the pain relief expected from the prescription.
Mistake to avoid: Treating a short opioid prescription as carrying no subsequent misuse risk for young patients.
Reference: [15]
55. Count acetaminophen across combination products
The 2024 ADA guide alerts patients that acetaminophen plus opioid combination tablets contain both drugs in one pill, so total daily acetaminophen must be reconciled across all products and should not exceed the guide's stated 4,000 mg per day.
Worked example: A patient reports taking six 500 mg standalone acetaminophen tablets plus four combination tablets each containing 325 mg acetaminophen; the day's total is 4,300 mg, above the guide's 4,000 mg maximum.
Mistake to avoid: Counting only the standalone acetaminophen tablets and ignoring acetaminophen hidden in combination pills.
Reference: [15]
Overdose reversal and emergency care
56. Naloxone reverses opioid effects through antagonism
Naloxone is an opioid antagonist: it binds to opioid receptors and can reverse and block the effects of other opioids. This contrasts with buprenorphine, an opioid partial agonist whose effects are weaker than those of full opioid agonists.
Worked example: When reviewing medication mechanisms, a team identifies naloxone as an antagonist that binds opioid receptors and can reverse and block other opioids' effects, distinguishing it from buprenorphine's partial agonist action.
Mistake to avoid: Assuming every medicine acting at opioid receptors produces the same kind of effect.
57. Apparent reversal does not end the emergency
Naloxone is a temporary treatment whose effects do not last long, so medical intervention is critical as soon as possible after an opioid overdose reversal medication is given. Emergency attention must not be delayed while awaiting a reversal response.
Worked example: After a dental team member administers a reversal medication, the patient briefly appears better; the team still summons emergency medical help immediately rather than postponing assessment because the initial response seemed reassuring.
Mistake to avoid: Telling a colleague that the patient looks fine now, so emergency evaluation can wait.
Reference: [13]
58. Overdose-prevention assessment includes distinct risk contexts
SAMHSA's candidate list includes several contexts for considering reversal medication, such as certain extended-release or long-acting opioid regimens, discharge after opioid poisoning, and a period of abstinence including recent release from incarceration. These are examples, not an exhaustive checklist.
Worked example: A patient returning to care after weeks of abstinence following release from incarceration is still considered for overdose-prevention assessment, since absence of recent prescribed opioid use does not by itself exclude this SAMHSA-listed context.
Mistake to avoid: Screening only the current prescription dose and skipping a patient recently released from incarceration.
Reference: [13]
59. Longer antagonist action can bring a withdrawal tradeoff
SAMHSA notes nalmefene has a higher half-life than naloxone, so it can stay in the body longer, and this can make withdrawal symptoms more severe and last longer. Longer duration alone therefore does not establish universal superiority of one reversal medication.
Worked example: A team discussion notes that nalmefene's longer presence in the body is described alongside possibly more severe, longer-lasting withdrawal, so duration is weighed as a tradeoff rather than read as an unconditional advantage over naloxone.
Mistake to avoid: Concluding nalmefene is automatically the better choice for every patient because it lasts longer.
Reference: [13]
60. Overdose reversal products have different access conditions
SAMHSA distinguishes FDA-approved over-the-counter naloxone nasal spray from nalmefene nasal spray, which is available by prescription only for individuals 12 years old and over. Product labeling and state-specific availability and restrictions should be checked rather than generalized.
Worked example: A practice keeps over-the-counter naloxone nasal spray available and separately confirms that its nalmefene nasal spray stock is prescription only for people 12 and older, checking state rules instead of assuming both products share the same access conditions.
Mistake to avoid: Assuming nalmefene nasal spray is also over the counter because a naloxone spray is.
Reference: [13]
Official references
- DEA Diversion Control Division: Registration Questions and Answers
- DEA: MATE Act—One-Time Training Requirement for Registered Practitioners
- SAMHSA: Recommendations for Curricular Elements in Substance Use Disorders Training
- DEA: Opioid Use Disorder—MATE Act Training and Attestation Questions and Answers
- DEA Practitioner's Manual, Revised 2023—Controlled-Substance Responsibilities for Dentists and Other Practitioners
- Current 21 CFR Part 1301: Controlled-Substance Registration and Security Requirements
- Current 21 CFR Part 1304: Records, Inventories and Reports of Registrants
- Current 21 CFR Part 1306: Controlled-Substance Prescription Requirements
- Current 21 CFR Part 1317: Disposal of Controlled Substances
- ADA Living Guideline: Adult and Adolescent Acute Dental Pain Management for Toothaches
- CDC Clinical Practice Guideline for Prescribing Opioids for Pain—United States, 2022
- SAMHSA: Buprenorphine—Treatment, Safety and Management of Opioid Use Disorder
- SAMHSA: Opioid Overdose Reversal Medications—Recognition, Naloxone and Emergency Response
- SAMHSA: Screening, Brief Intervention and Referral to Treatment
- ADA: Temporary Pharmacologic Management of Acute Dental Pain—Toothache in Adolescents, Adults, and Older Adults Without Immediate Definitive Treatment (2024 chairside guide)
- NIAAA: Screen and Assess—Use Quick, Effective Methods
- NIAAA: Conduct a Brief Intervention—Build Motivation and a Plan for Change
- U.S. Public Health Service: Treating Tobacco Use and Dependence—2008 Update, Complete Clinical Practice Guideline (historical edition)